ArticleOpen forum infectious diseases2017
Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature.
Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Pharmacist-Led Full-Course Pharmaceutical Care Model in Allergic Bronchopulmonary Aspergillosis: A Case Report-Based Approach to Optimizing Multidisciplinary Management.Infection and drug resistance · 2026Article
- Asthma and Allergic Bronchopulmonary Aspergillosis: Understanding, Insights, and State-of-the-Art.Journal of inflammation research · 2026Review
- Preparation and Evaluation of Inhalable Microparticles with Improved Aerodynamic Performance and Dispersibility Using L-Leucine and Hot-Melt Extrusion.Pharmaceutics · 2024Article
- Molecular Characterization and Antifungal Susceptibility ofTropical medicine and infectious disease · 2022Article
- Isavuconazole-Animal Data and Clinical Data.Journal of fungi (Basel, Switzerland) · 2020Review
- Allergic Bronchopulmonary Aspergillosis in Children with Cystic Fibrosis: An Update on the Newest Diagnostic Tools and Therapeutic Approaches.Pathogens (Basel, Switzerland) · 2020Review
- Allergic bronchopulmonary aspergillosis.The Indian journal of medical research · 2020Review
- Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.Frontiers in pediatrics · 2020Review
- Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019Review
- A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.European journal of drug metabolism and pharmacokinetics · 2018Review
- Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?Mycopathologia · 2017Article
- Successful treatment of allergic bronchopulmonary aspergillosis with posaconazole in a child with cystic fibrosis: Case report and review of the literature.Lung India : official organ of Indian Chest SocietyArticle
- Childhood allergic bronchopulmonary aspergillosis.Lung India : official organ of Indian Chest SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isavuconazole is a new triazole that is approved for primary therapy of invasive aspergillosis. We provide the first report of a patient with allergic bronchopulmonary aspergillosis (ABPA) who was successfully treated with isavuconazole with marked improvement and minimal adverse effects. We further review the literature on antifungal management of ABPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.